Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT05397171 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | terminated | Phase 1 / Phase 2 | 17 | AstraZenecaINDUSTRY | 2 | Oct 1, 2024 |
| clinicaltrials |
| NCT03716596 | SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients(CISPD-2) | terminated | Phase 1 | 8 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 30 | Biosplice Therapeutics, Inc.INDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT05352542 | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 10 | jianming xuOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | terminated | Phase 1 / Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | NextCure, Inc.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | terminated | Phase 1 / Phase 2 | 89 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | terminated | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 21 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 3 | Jul 11, 2024 | clinicaltrials |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | terminated | Phase 1 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05160168 | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 1 / Phase 2 | 32 | Theseus PharmaceuticalsINDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX(SLC-0111-17-01) | terminated | Phase 1 / Phase 2 | 6 | British Columbia Cancer AgencyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03730948 | DC Vaccine in Colorectal Cancer | terminated | Phase 1 | 4 | University of PennsylvaniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | terminated | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | May 23, 2024 | clinicaltrials |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | terminated | Phase 1 | 8 | Academic and Community Cancer Research UnitedOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04073615 | A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) | terminated | Phase 1 | 29 | Elevar TherapeuticsINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT00838578 | Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 65 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03558724 | Fluorescence Endoscopy of Esophageal Carcinoma(ORCA) | terminated | Phase 1 | 25 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04718402 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma | terminated | Phase 1 | 21 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 92 | Gilead SciencesINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | terminated | Phase 1 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma | terminated | Phase 1 | 29 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 2, 2024source: clinicaltrials